U.S. Markets closed

iBio, Inc. (IBIO)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.2640-0.0139 (-5.00%)
At close: 04:00PM EDT
0.2730 +0.01 (+3.41%)
After hours: 04:24PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2779
Bid0.2600 x 3100
Ask0.2621 x 4000
Day's Range0.2600 - 0.2879
52 Week Range0.2200 - 1.5200
Avg. Volume2,938,303
Market Cap57.541M
Beta (5Y Monthly)-5.38
PE Ratio (TTM)N/A
EPS (TTM)-0.1190
Earnings DateFeb 14, 2022 - Feb 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.75
  • GlobeNewswire

    iBio to Participate in the H.C. Wainwright Global Investment Conference

    BRYAN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming® Manufacturing System, today announced that it will participate virtually in the H.C. Wainwright Global Investment Conference. The hybrid conference will take place May 23-26, 2022. iBio's pre-recorded presentation will be available on demand during the event for all registered attendees. Begin

  • Motley Fool

    iBio (IBIO) Q3 2022 Earnings Call Transcript

    Before we begin, I would like to remind you that during this call, the company will be making forward-looking statements regarding our current expectations and projections about future events that are subject to risks and uncertainties. No forward-looking statements can be guaranteed and actual results may differ from the results discussed in the forward-looking statements.

  • GlobeNewswire

    iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update

    BRYAN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announces its financial results for the fiscal quarter ended March 31, 2022 and provides a corporate update.“In this quarter, we took multiple steps forward towards becoming a clinical-stage company – a potentially major value inflection point,” said Tom Isett, Chairman & CEO of